We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
AstraZeneca has received the European Commission (EC) approval for expanded indication of Forxiga (dapagliflozin) to include heart failure (HF) with reduced ejection fraction (HFrEF). Forxiga is an oral,
Israel-based CNS-first clinical-stage company Clexio Biosciences has teamed up with Genetika+, a developer of personalised medicine for psychiatric and neurological diseases. The partnership is aimed to screen and
US-based Gilead Sciences has received the US Food and Drug Administration (FDA) approval for Trodelvy (sacituzumab govitecan-hziy) to treat a type of breast cancer in adults. Trodelvy is
AstraZeneca and Amgen announced that the US Food and Drug Administration (FDA) has approved Tezspire (tezepelumab) for self-administration in a pre-filled, disposable pen for patients with severe asthma,
British drugmaker GSK has received the US Food and Drug Administration (FDA) approval for Jesduvroq (daprodustat) to treat anaemia caused by chronic kidney disease (CKD). Jesduvroq is an
US-based biotechnology company Amgen has announced the US commercialisation of Amjevita (adalimumab-atto), its biosimilar to AbbVie’s antibody therapy Humira (adalimumab). Amjevita’s active pharmaceutical ingredient (API) is an anti-TNF-α
Kite Pharma, a company of Gilead, has closed a previously announced strategic collaboration with Arcellx, a clinical-stage biotechnology company focused on cell therapy. In December last year, the
Loxo@Lilly, the oncology unit of Eli Lilly and Company (Lilly), has received the US Food and Drug Administration (FDA) approval for Jaypirca (pirtobrutinib) to treat a type of
AstraZeneca and Daiichi Sankyo announced that the European Commission (EC) has approved Enhertu (trastuzumab deruxtecan) to treat a type of breast cancer in adults. Enhertu is an antibody-drug
Eli Lilly and Company (Lilly) is planning to invest around $450m to expand the manufacturing capacity of its Research Triangle Park facility in North Carolina, US. The expansion